Literature DB >> 1316371

MIC and disk diffusion quality control guidelines for Neisseria gonorrhoeae susceptibility tests of cefdinir, cefetamet, CI-960, fleroxacin, lomefloxacin, and temafloxacin.

M E Erwin1, R N Jones, F P Koontz, E H Gerlach, P R Murray, J A Washington.   

Abstract

Cefdinir (FK482), cefetamet (Ro 15-8074), CI-960, fleroxacin, lomefloxacin, and temafloxacin have potent activities against Neisseria gonorrhoeae. They were tested in a multilaboratory study to establish quality control guidelines. Quality control ranges for N. gonorrhoeae ATCC 49226 were determined by using multiple GC agar lots, three disk lots, and a number of test replicates consistent with the M23-T guidelines of the National Committee for Clinical Laboratory Standards. The MIC ranges included 2 to 4 log2 dilution steps. The recommended inhibition zone diameter ranges were generally 7 to 8 mm and included greater than or equal to 91.3% of all recorded study results.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1316371      PMCID: PMC265275          DOI: 10.1128/jcm.30.5.1317-1319.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628.

Authors:  M S Barrett; R N Jones; M E Erwin; D M Johnson; B M Briggs
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Sep-Oct       Impact factor: 2.803

2.  Different doses of cefetamet pivoxil (Ro 15-8075) in the treatment of acute uncomplicated gonococcal urethritis in men.

Authors:  T T Tio; I R Sindhunata; J H Wagenvoort; M F Michel; E Stolz
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

3.  In vitro and in vivo activity of NY-198, a new difluorinated quinolone.

Authors:  T Hirose; E Okezaki; H Kato; Y Ito; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

4.  Preliminary antimicrobial susceptibility interpretive criteria for cefetamet (Ro 15-8074) and cefteram (Ro 19-5247) disk tests.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

5.  Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline.

Authors:  R N Jones; T L Gavan; C Thornsberry; P C Fuchs; E H Gerlach; J S Knapp; P Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

6.  Proposed interpretive criteria and quality control parameters for testing in vitro susceptibility of Neisseria gonorrhoeae to ciprofloxacin.

Authors:  P C Fuchs; A L Barry; C Baker; P R Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

7.  In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin.

Authors:  B M Briggs; R N Jones; M E Erwin; M S Barrett; D M Johnson
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Sep-Oct       Impact factor: 2.803

8.  Development of Neisseria gonorrhoeae in vitro susceptibility test methods for cefixime including quality control guidelines.

Authors:  R N Jones; E H Gerlach; F P Koontz; P R Murray; M A Pfaller; J A Washington; M E Erwin; C C Knapp
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Sep-Oct       Impact factor: 2.803

9.  Fleroxacin versus standard therapy in gonococcal urethritis.

Authors:  A Lassus; O V Renkonen; J Ellmén
Journal:  J Antimicrob Chemother       Date:  1988-10       Impact factor: 5.790

10.  In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.

Authors:  K Hirai; H Aoyama; M Hosaka; Y Oomori; Y Niwata; S Suzue; T Irikura
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

View more
  2 in total

Review 1.  Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

Review 2.  Antimicrobial susceptibility testing of Neisseria gonorrhoeae and implications for epidemiology and therapy.

Authors:  T Fekete
Journal:  Clin Microbiol Rev       Date:  1993-01       Impact factor: 26.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.